Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCT301-38 in AXL Positive Sarcomas
NCT05128786Phase 1Terminated
- Sponsor
- Shanghai PerHum Therapeutics
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CCT301-38 in sarcoma, sponsored by Shanghai PerHum Therapeutics. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Dec 2021; status: terminated.
02
Drugs
CCT301-38
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT05128786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128786.